CYXONE
Cyxone AB is a Swedish biotech company founded in 2015 with the aim of developing drugs with cyclotide technology that can considerably improve quality of life for people living with severe autoimmune diseases. The company is run via an international network of different experts within research, development and manufacturing, including the scientific founders in Austria and Germany. The driving force is to develop a strong drug portfolio with innovative and effective treatment methods to decreas... e the side effects and slow down the disease development in order to improve quality of life for people affected by severe immune-related disorders. Cyxone’s portfolio is based on a solid research platform with a type of biological molecules that have proven to work well as a drug for humans. The company’s development portfolio comprises Rabeximod in clinical phase II program for rheumatoid arthritis (RA) and T20K that is in clinical phase I for multiple sclerosis (MS). In future, Cyxone will also use its cyclotide technology to develop new structures that may prove beneficial for patients in other disease areas.
CYXONE
Industry:
Biotechnology
Address:
Malmö, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.cyxone.com
Total Employee:
1+
Status:
Active
Contact:
+46 (0)723 816 168
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Apache
Similar Organizations
Current Employees Featured
Official Site Inspections
http://www.cyxone.com Semrush global rank: 4.93 M Semrush visits lastest month: 1.74 K
- Host name: webcluster1.wordpresspod2-cph3.one.com
- IP address: 77.111.241.74
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Cyxone"
Cyxone - Crunchbase Company Profile & Funding
Organization. Cyxone . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Cyxone AB is a Swedish biotech company founded in 2015 with the aim of …See details»
Start - Cyxone
Nov 26, 2024 Om Cyxone Cyxone utvecklar nya innovativa terapier för behandling av reumatoid artrit och multipel skleros. Vi har som mål att med våra läkemedel ge ökad livskvalitet för patienter som är i behov av ett mer effektivt, …See details»
Investor Relations - Cyxone
Jul 23, 2024 Cyxone AB is a clinical stage biotech company specializing in the development of transformative therapies against autoimmune and autoinflammatory diseases. Our pipeline includes rabeximod, currently in …See details»
Cyxone AB (publ) (STO:CYXO) Company Profile & Overview
Dec 5, 2024 Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises …See details»
Cyxone Company Profile - Office Locations, Competitors, Revenue …
Cyxone is a biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. It develops pipeline drug products such as …See details»
Cyxone Switzerland AG - Swiss Biotech
Cyxone develops novel drugs to improve quality of life for patients suffering from autoimmune diseases. Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as …See details»
Cyxone AB - Drug pipelines, Patents, Clinical trials - Synapse
Explore Cyxone AB with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 8 news, Drug:T-20K, Rabeximod.See details»
Ola Skanung - CFO at Cyxone - The Org
Cyxone. Ola Skanung; Ola Skanung. CFO at Cyxone. Contact. Ola has a background as a Master of Business Administration, majoring in entrepreneurship, with further studies in change …See details»
New management at Cyxone - BioStock
Jun 22, 2022 The board of Malmö-based company Cyxone recently announced a change in management. Carl-Magnus Högerkorp, Chief Operating Officer, steps in as acting CEO and replaces Tara Heitner, who resigns with immediate …See details»
Cyxone receives in total SEK 21.8 million in proceeds from fully ...
Oct 2, 2020 Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that the investment option agreement …See details»
Newsletter Archives - Cyxone
Much is ongoing within the organization and we are in the... Read More. Newsletter November 2019. Nov 7, 2019 ... Cyxone has kept a low profile while we prepared for our clinical studies …See details»
Cyxone Explores Orphan Drug Designation for Rabeximod
STOCKHOLM, Sept. 4, 2019 /PRNewswire/ -- Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided …See details»
Cyxone AB (@CyxoneTx) - Twitter
Jan 18, 2022 The latest Tweets from Cyxone AB (@CyxoneTx). We are a Swedish biotechnology company developing transformative therapies for autoimmune diseases. Follow …See details»
Cyxone AB i konkurs | Kreditrapporten.se
Om företaget. Cyxone AB försattes i konkurs 2024-12-09. Det grundades 2015 och var verksamt inom branschen Annan naturvetenskaplig och teknisk forskning och utveckling.Företaget hade …See details»
Cyxone is exploring new treatment possibilities for T20K
Jul 15, 2021 Recently, Malmö-based company Cyxone announced the next development steps for its drug candidate T20K in the treatment of multiple sclerosis (MS). While continuing to …See details»
Press Release - Cyxone
Oct 27, 2023 Cyxone carries out a rights issue of shares of approximately MSEK 36.3 ; Significant events after the end of the period. ... Very recently we submitted an extensive …See details»
Cyxone In Partnership With Contract Development ... - TradingView
Jan 18, 2022 cyxone ab c cyxo: cyxone takes next step in multiple sclerosis program engaging contract development & manufacturing organization for production of t20k. collaboration will …See details»
Article in BioStock: World MS Day: Cyxone aims to deliver better, …
May 29, 2019 BioStock published an article about Cyxone on 29 May 2019, which can be read below. As mainstream MS treatments get scolded by the FDA and the EMA after reports from …See details»
Avstämningsdag för tilldelning av teckningsoptioner av serie TO4 …
Den 10 november 2020 beslutade styrelsen för Cyxone AB (publ), (”Cyxone” eller ”Bolaget”) om en riktad emission (den ”Riktade Emissionen”) och att emittera teckningsoptioner av serie TO4 …See details»